CN1293906C - Chinese medicine preparation for treating rheumatism stagnation-syndrome pain - Google Patents
Chinese medicine preparation for treating rheumatism stagnation-syndrome pain Download PDFInfo
- Publication number
- CN1293906C CN1293906C CNB2004100110987A CN200410011098A CN1293906C CN 1293906 C CN1293906 C CN 1293906C CN B2004100110987 A CNB2004100110987 A CN B2004100110987A CN 200410011098 A CN200410011098 A CN 200410011098A CN 1293906 C CN1293906 C CN 1293906C
- Authority
- CN
- China
- Prior art keywords
- present
- chinese medicine
- parts
- starch
- dampness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 208000002193 Pain Diseases 0.000 title abstract description 25
- 208000011580 syndromic disease Diseases 0.000 title description 2
- 208000006820 Arthralgia Diseases 0.000 claims abstract description 23
- 241000908494 Dioscorea nipponica Species 0.000 claims abstract description 15
- 235000017008 Dioscorea nipponica Nutrition 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims abstract description 13
- 235000019698 starch Nutrition 0.000 claims abstract description 13
- 239000008107 starch Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001035 drying Methods 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 208000025747 Rheumatic disease Diseases 0.000 claims description 11
- 230000000552 rheumatic effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000009495 sugar coating Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 241001528016 Ventilago Species 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 238000009501 film coating Methods 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 239000002574 poison Substances 0.000 abstract 1
- 231100000614 poison Toxicity 0.000 abstract 1
- 239000010409 thin film Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000003068 rheumatic fever Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002105 tongue Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 2
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 2
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Group | Dosage (gram/kilogram) | Number of animals (only) | Turn round the body number of times |
The present invention | 12.0 | 10 | 18.2±5.9 * |
The present invention | 8.0 | 10 | 20.1±4.6 |
The present invention | 4.0 | 10 | 22.9±4.9 |
QUFENG ZHITONG JIAONANG | 8.0 | 10 | 17.3±6.1 * |
Blank | 10 | 26.8±7.2 |
Group | Dosage (gram/kilogram) | Number of animals (only) | Turn round the body number of times |
The present invention | 12.0 | 10 | 6.45±1.36 ** |
The present invention | 8.0 | 10 | 8.35±1.77 |
The present invention | 4.0 | 10 | 7.52±1.68 * |
QUFENG ZHITONG JIAONANG | 8.0 | 10 | 7.64±1.71 |
Blank | 10 | 9.60±1.74 |
Group | Number of animals (only) | Dosage (gram/kilogram) | The survival number of elements | Survival rate (%) |
Blank | 10 | 3 | 30 | |
The present invention | 10 | 12 | 8 Δ | 80 |
The present invention | 10 | 8 | 6 | 60 |
The present invention | 10 | 4 | 4 | 40 |
QUFENG ZHITONG JIAONANG | 10 | 8 | 6 | 60 |
Age | The state of an illness | The course of disease | The symptom scores accumulated | |||||||||
Maximum | Minimum | On average | Slight person | Moderate person | Severe person | The shortest | The longest | On average | Minimum | At most | On average | |
Experimental group 300 examples | 65 | 18 | 3915± 10.74 | 75 | 179 | 46 | 3 months | 6 years | 2.19 ±1.38 | 9 | 26 | 14.39 ±3.79 |
Matched group 100 examples | 64 | 18 | 39.13 ±11.37 | 30 | 60 | 10 | 3 months | 5 years | 2.04 ±1.33 | 8 | 25 | 14.27 ±4.15 |
Symptom | Heavy (3 minutes) | In (2 minutes) | Gently (1 minute) | Do not have (0 minute) |
*Arthralgia | Severe pain is difficult because of bearing | Pain still can be stood | Pain slightly | No pain |
*Limbs are heavy | Heavy obvious, influence activity | Heavyly obviously influence activity slightly | The heavy activity that do not influence is arranged slightly | No sense of heaviness |
Local cool | Obviously there is cool sense the part, very then is in a cold sweat | There are cool sense, no cold sweat in the part | The part has cool sense slightly | There is not cool sense |
Swelling | Swelling is obvious | Swelling | Swelling slightly | No swelling |
Local fear of cold | Local fear of cold is obvious | Local fear of cold | Local milli fear of cold | No fear of cold |
Meet the cold pain that increases | Meeting cold pain obviously increases | Meeting cold pain increases | Meeting cold pain increases slightly | Meeting cold pain does not increase |
Picture of the tongue | (counting 1 fen) arranged | Do not have (counting 0 fen) | ||
Pulse condition | (counting 1 fen) arranged | Do not have (counting 0 fen) |
Group | The example number | Clinic control | Produce effects | Effectively | Invalid | Show control rate % | Total effective rate % |
Example (%) | Example (%) | Example (%) | Example (%) | ||||
Test group | 300 | 47(15.67) | 123(41) | 98(32.67) | 32(10.67) | 56.67 | 89.33 |
Matched group | 100 | 13(13) | 26(26) | 38(38) | 23(23) | 39 | 77 |
The sick kind | The example number | Clinic control | Produce effects | Effectively | Invalid | Show control rate % | Total effective rate % |
Example (%) | Example (%) | Example (%) | Example (%) | ||||
Arthritis | 56 | 6(10.71) | 15(26.79) | 22(39.29) | 13(23.21) | 37.5 | 76.79 |
Arthralgia | 244 | 41(16.80) | 108(44.26) | 76(31.15) | 19(7.79) | 61.06 | 92.21 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100110987A CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100110987A CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1748763A CN1748763A (en) | 2006-03-22 |
CN1293906C true CN1293906C (en) | 2007-01-10 |
Family
ID=36604540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100110987A Expired - Lifetime CN1293906C (en) | 2004-09-17 | 2004-09-17 | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1293906C (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073870A (en) * | 1992-10-26 | 1993-07-07 | 常民 | The preparation method of neck-building medicine |
CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
-
2004
- 2004-09-17 CN CNB2004100110987A patent/CN1293906C/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073870A (en) * | 1992-10-26 | 1993-07-07 | 常民 | The preparation method of neck-building medicine |
CN1490017A (en) * | 2002-10-14 | 2004-04-21 | 何廷银 | Medicines against rheunatoid and rheumatic diseases |
Also Published As
Publication number | Publication date |
---|---|
CN1748763A (en) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103463539B (en) | A kind of medicine for the treatment of eczema and its production and use | |
CN100358549C (en) | Diarrhea treating chinese medicine composition | |
CN103120719A (en) | Pure traditional Chinese medicine composition for treating sacbrood virus of bees and preparation method thereof | |
CN103705796B (en) | A kind of pharmaceutical composition for the treatment of diarrhoea and preparation method thereof | |
CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
CN104524247B (en) | One treats migrainous medical composition and its use | |
CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
CN1293906C (en) | Chinese medicine preparation for treating rheumatism stagnation-syndrome pain | |
CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
CN103860894B (en) | A kind of medicine for the treatment of chronic prostatitis | |
CN104622995A (en) | Pharmaceutical composition for treating chronic superficial gastritis and preparation method of pharmaceutical composition | |
CN1943701B (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
CN1209162C (en) | Medicinal composition for treating acne and chloasma | |
CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
CN106943554A (en) | A kind of Chinese medicine composition for being used to treat chordapsus | |
CN1284588C (en) | Medicine for treating gastrointestinal tract diseases | |
CN1951464A (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
CN1313142C (en) | Pharmaceutical composition with exterior syndrome easing, cough and asthma easing function | |
CN104958530A (en) | Traditional Chinese medicinal composition for treating infantile pneumonia | |
CN1751596A (en) | Health-care food and its soft capsule for improving immunity of anti alimentary canal infection, and its prepn. method | |
CN102552706B (en) | Medicine for treating vascular dementia and preparation method thereof | |
CN116726083A (en) | Traditional Chinese medicine composition for treating chronic prostatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: XIUZHENG PHARMACEUTICAL GROUP BEIJING XIUZHENG PHARMACEUTICAL CO.,LTD. Assignor: Xiu Laigui Contract fulfillment period: 2008.6.28 to 2018.6.27 Contract record no.: 2009110000066 Denomination of invention: Chinese medicine preparation for treating rheumatism stagnation-syndrome pain Granted publication date: 20070110 License type: Exclusive license Record date: 20090505 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.6.28 TO 2018.6.27; CHANGE OF CONTRACT Name of requester: XIUZHENG PHARMACEUTICAL INDUSTRY GROUP BEIJING XIU Effective date: 20090505 |
|
ASS | Succession or assignment of patent right |
Owner name: TONGYAO PHARMACEUTICAL GROUP STOCK CO., LTD. Free format text: FORMER OWNER: XIU LAIGUI Effective date: 20150525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 130012 CHANGCHUN, JILIN PROVINCE TO: 134000 TONGHUA, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150525 Address after: 134000 amendment Road 39, Jilin, Tonghua Patentee after: Tongyao Pharmaceutical Group Corp. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Xiu Laigui |
|
CX01 | Expiry of patent term |
Granted publication date: 20070110 |